| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | Transcript: Sanara MedTech Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 11.05. | Sanara MedTech GAAP EPS of $0.04, revenue of $27.8M | 1 | Seeking Alpha | ||
| 11.05. | Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited) | 145 | GlobeNewswire (Europe) | Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara... ► Artikel lesen | |
| 11.05. | Sanara MedTech Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 06.04. | H.C. Wainwright reiterates Sanara MedTech stock rating at buy | 1 | Investing.com | ||
| 06.04. | H.C. Wainwright bestätigt Kaufempfehlung für Sanara MedTech | 1 | Investing.com Deutsch | ||
| 24.03. | Sanara MedTech Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| SANARA MEDTECH Aktie jetzt für 0€ handeln | |||||
| 24.03. | Sanara MedTech outlines 2026 net revenue guidance of $116M-$121M while expanding distributor network and product reach | 2 | Seeking Alpha | ||
| 24.03. | Sanara MedTech-Aktie steigt trotz verfehlter Quartalserwartungen | 1 | Investing.com Deutsch | ||
| 24.03. | Sanara MedTech GAAP EPS of -$0.19, revenue of $27.5M | 2 | Seeking Alpha | ||
| 24.03. | Sanara MedTech Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.03. | Sanara MedTech study shows cost savings with CellerateRX powder | 1 | Investing.com | ||
| 11.03. | Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX Surgical Powder in the Management of Spine Surgery Wounds | 1 | GlobeNewswire (USA) | ||
| 03.03. | Sanara MedTech auf TD Cowen Konferenz: Strategische Neuausrichtung auf den Chirurgiemarkt | 3 | Investing.com Deutsch | ||
| 03.03. | Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 | 1 | GlobeNewswire (USA) | ||
| 02.03. | Sanara MedTech Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.01. | Sanara MedTech expects Q4 revenue between $27.2M and $27.7M | 1 | Seeking Alpha | ||
| 23.01. | Sanara MedTech expects 19% revenue growth for 2025, issues 2026 guidance | 2 | Investing.com | ||
| 23.01. | Sanara MedTech Inc. - 8-K, Current Report | 2 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALIGNMENT HEALTHCARE | 13,290 | -0,08 % | Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation | ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further strengthen the organization as the company continues to scale... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,00 | +0,03 % | BrightSpring Health Services, Inc. (BTSG) is on the Move, Here's Why the Trend Could be Sustainable | ||
| FRESENIUS | 35,280 | -0,48 % | dpa-AFX-Überblick: UNTERNEHMEN vom 26.05.2026 - 15.15 Uhr | Schwerwiegende Bedenken: BP trennt sich von Verwaltungsratschef - Kursrutsch LONDON - Der britische Ölkonzern BP setzt seinen Verwaltungsratschef Albert Manifold wegen Vorwürfen vor die Tür. Als... ► Artikel lesen | |
| GENEDX | 52,00 | 0,00 % | GeneDx (WGS) Fell Despite Continued Execution Improvement | ||
| QTREX QUANTUM | 3,100 | +0,65 % | QTREX Quantum Ltd. - 6-K, Report of foreign issuer | ||
| BILLIONTOONE | 90,86 | -0,29 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 27,860 | 0,00 % | Procept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollment | ||
| PROGYNY | 26,210 | +0,04 % | Progyny, Inc.: New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System | ||
| HEARTFLOW | 30,950 | -0,16 % | Heartflow, Inc.: Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 35,980 | -1,15 % | EQS-Adhoc: Fresenius Medical Care AG: Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit einem Gesamtvolumen von rund EUR 1 Milliarde in Tranchen | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Kapitalmaßnahmen / Aktienrückkäufe
Fresenius Medical Care AG: Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,280 | +0,06 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung (EU)... ► Artikel lesen | |
| ALPHA TAU MEDICAL | 9,665 | 0,00 % | Alpha Tau Medical Ltd.: Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting | - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of... ► Artikel lesen | |
| ADAPTHEALTH | 9,910 | -0,20 % | AdaptHealth Corp. - 10-Q, Quarterly Report | ||
| PRIVIA HEALTH GROUP | 21,300 | -0,05 % | Privia Health Group, Inc.: Privia Health Enters New Jersey | ||
| UNITEDHEALTH | 325,80 | -0,24 % | EILMELDUNG bei Unitedhealth: Könnte die Aktie jetzt komplett einbrechen? - Meine klare Einschätzung dazu |